<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:obo="http://purl.obolibrary.org/obo/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>                            NIH Public Access <br />                             Author Manuscript <br />                             Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01. <br />                            Published final edited form  <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                             Expert Opin Drug Discov. 2013 December ; 8(12): . doi:10.1517/17460441.2013.845554. <br />  <br />  <br />  <br />                            Design screening drugs treatment Chagas <br />                            disease: shows promise? <br />                            Galina  Lepesheva <br />                            Vanderbilt University, Institute Global Health, School Medicine, Center Structural <br />                            Biology, Department Biochemistry, Nashville, TN, USA <br />  <br />                            Abstract <br />                                 Introduction&#226;&#8364;&#8221;Endemic Latin America, Chagas disease global <br />                                 health problem, financial viability pharmaceutical industry remains <br />                                 incurable. 2012, antimycotic drugs inhibitors fungal sterol 14&#206;&#177;-demethylase (CYP51) &#226;&#8364;&#8220; <br />                                 posaconazole ravuconazole &#226;&#8364;&#8220; entered clinical trials. Availability X-ray structure                                 orthologous enzyme causative agent disease, protozoan parasite Trypanosoma <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                 cruzi, determined complexes posaconazole experimental protozoa- <br />                                 specific CYP51 inhibitors opens excellent opportunity improve situation. <br />                                 Areas covered article summarizes information available PubMed Google                                 outcomes treatment chronic Chagas disease. outlines major features                                 T. cruzi CYP51 structure possible structure-based strategies rational design novel T. <br />                                 cruzi specific drugs. <br />                                 Expert opinion doubt screenings alternative drug-like molecules                                 mining T. cruzi genome novel drug targets great value eventually lead                                 groundbreaking discoveries.  newly identified molecules proceed                                 long, expensive low-yielding drug optimization process, novel potential drug targets <br />                                 validated terms essentiality druggability. CYP51 validated <br />                                 highly successful target clinical agricultural antifungals. minimal investments <br />                                 final stages development/trials, T. cruzi-specific CYP51 inhibitors provide                                 immediate treatment Chagas disease, combination currently <br />                                 available drugs. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                            Keywords <br />                                 Chagas disease; drug discovery; sterol 14&#206;&#177;-demethylase (CYP51) inhibitors; sterol biosynthesis; <br />                                 structure-based drug design; Trypanosoma cruzi <br />  <br />  <br />                            1. Introduction <br />                                              Chagas disease, known American trypanosomiasis, life-long infection, <br />                                              anthropozoonosis caused unicellular flagellate protozoan parasite Trypanosoma cruzi <br />                                              (class Kinetoplastida) [1&#226;&#8364;&#8220;3]. pathogen, described 1909 Carlos Chagas,  <br />  <br />  <br />                            &#194;&#169; 2013 Informa UK,  <br />                            Galina Lepesheva PhD, Research Associate Professor, Vanderbilt University, Institute Global Health, School Medicine, <br />                            Center Structural Biology, Department Biochemistry, 622 RRB, 23rd Pierce, Nashville, TN 37232, USA, Tel: +1 615 343 <br />                            1373; Fax: +1 615 322 4349; galina lepesheva@vanderbilt.edu <br />                            Declaration                            GI Lepesheva declares support form grant National Institutes Health (R01 GM067871). <br />                             Lepesheva                                                                                             Page 2 <br />  <br />  <br />                                         complex life cycle, involving developmental stages: proliferative epimastigote                                         infective metacyclic trypomastigote hematophagous triatomine vectors (&#226;&#8364;&#732;kissing bugs&#226;&#8364;&#8482;); <br />                                         proliferative intracellular amastigotes infective bloodstream trypomastigotes NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         humans variety mammalian hosts (&gt; 150 species) form disease reservoir. <br />                                         insect stages T. cruzi develop kissing bug hindgut transmitted                                         mammals bug feces deposited blood feeding itchy bite wound                                         mucous membranes. mammals, parasites soon exit bloodstream invade                                         cytoplasm host cells. various cell types infected, chronic disease                                         associated mainly cardiac enteric tissues. Non-vector-borne routes T. cruzi <br />                                         transmission include congenital  mother child, 1 &#226;&#8364;&#8220; 10% newborn babies                                         endemic countries [4]), transfusion infected blood, organ transplantation, ingestion                                         food liquid contaminated T. cruzi, generally associated massive <br />                                         parasitic infestation, resulting severe acute clinical presentation high mortality <br />                                         [5,6]. <br />  <br />                                         Clinically, disease characterized phases: acute, indeterminate chronic. <br />                                         acute phase, T. cruzi easily detected blood. parasitemia goes <br />                                          making diagnostics complicated. severity acute phase,                                         lasts 4 &#226;&#8364;&#8220; 8 weeks, depends different factors, parasite load strain, <br />                                         patient immune response varies mild unrecognized flu-like illness                                         symptoms hepatosplenomegaly, meningoencephalitis myocarditis, fatality rate NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         &lt; 5%. indeterminate phase generally asymptomatic comprises period                                         10 &#226;&#8364;&#8220; 20 years.  ~ 30% infected patients develop chronic form                                         disease, cardiac (arrhythmias, congestive heart failure, cardiac enlargement, <br />                                         thromboembolism sudden cardiac death), digestive (megaoesophagus mega colon) <br />                                         cardiodigestive [1,7&#226;&#8364;&#8220;9]. 60% patients chronic Chagas disease die 7 months <br />                                         2 years onset symptoms [10]. risk disease activation sharply <br />                                         increases immunodeficient patients (immunosuppressant therapies [11], HIV coinfections <br />                                         [12]). <br />  <br />                                         Chagas disease afflicting humans South America 9,000 years, 41% <br />                                         prevalence rate tissue specimens human mummies reported [13]. Sadly <br />                                          infection remains endemic 18 countries, represents                                         leading causes morbidity, long-term disability mortality [14]. late 1970s, 20% <br />                                         Bolivian population estimated infected T. cruzi, rural areas <br />                                         provided prevalence rates 40 80% [15]. past decades,                                          statistics certainly improved. 1990 reported 18 million infected, <br />                                         700,000 new cases 50,000 deaths year South Central America, 2000                                         corresponding numbers declined 200,000 new cases 21,000 deaths year [16] NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         ~ 10 million infected reported 2010 [17]. improvement largely <br />                                         extensive vector donor blood bank control programs endemic areas [1,6], <br />                                         change prevailing view nature disease. <br />  <br />                                         decades drug development Chagas basically halted &#226;&#8364;&#732;outstanding <br />                                         influence&#226;&#8364;&#8482; [2] called neurogenic postulate followed autoimmune hypothesis,                                         essentially based data obtained insufficient sensitivity                                         techniques employed stated chronic form Chagas considered                                         infectious disease inflammatory disease/imbalanced immune response. <br />                                         Consequently, specific antiparasitic treatment declared irrelevant abandoned,                                         treatment aimed mitigate symptoms  antiarrhythmic drugs, <br />                                         pacemakers heart transplantation [1]) remained provided. example, according                                         autoimmune hypothesis, parasite triggers autoimmune response                                         hosts, persistence does play role disease pathogenesis.  <br />  <br />  <br />                                        Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01. <br />                             Lepesheva                                                                                               Page 3 <br />  <br />  <br />                                         successful antiparasitic treatment lead improvement clinical <br />                                         outcome [2,18]. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         Fortunately,  recent studies, using sensitive methods demonstrated clear <br />                                         correlation inflammatory processes presence parasite [19],                                         supporting alternative opinion eradication T. cruzi infected patients                                         prerequisite cure disease [20&#226;&#8364;&#8220;23], ). prevailing view begun change; <br />                                          damage  disease acquired status incurable,                                         consequently, highly neglected, turn delayed development  <br />                                         specific etiological treatment, ii) efficient diagnostics iii) cure evaluation criteria [9]. <br />                                         past years, certain progress achieved fields. article <br />                                         concentrate aspect: specific antiparasitic chemotherapy,                                         focusing CYP51 inhibitors. <br />  <br />                                         modern strategies develop antitrypanosomal treatment Chagas disease include <br />                                         phenotypic  organism) screening libraries biologically active small molecules <br />                                         new chemotypes trypanocidal activity, fast vivo screening compounds <br />                                         identified vitro, mining T. cruzi genome new drug targets; searching efficient <br />                                         inhibitors potential targets (proteins/DNA) confirmed essential                                         parasite survival. approaches highly promising eventually lead                                         pioneering discoveries. lack knowledge molecular target/mechanism NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         compounds identified phenotypic screening make lead optimization process <br />                                         highly challenging. hand, target selection minefield potential issues, <br />                                         target essential, druggable available <br />                                         assay vitro.  process certainly time requires significant financial <br />                                         investments. Pharmaceutical companies,  remain reluctant invest resources                                         development antichagasic drugs, especially lack assurances                                         make return investment. <br />  <br />                                         meantime, Chagas disease severe global medical challenge, mainly                                         human/vector migration [24], lack awareness diagnostics                                         nonendemic areas [25,26]. estimates indicate 1 million cases                                         Chagas disease United States [27], 267,000 cases Texas [28]. <br />                                         majority infected reported immigrants Latin America [29].                                         known infected insects widely spread southern states                                         country, largely feeding wild animals  2007, 30% armadillos 38%                                         opossums Louisiana infected T. cruzi [27]), occasionally affecting <br />                                         domestic dogs (e.g., 537 confirmed canine cases Chagas disease 1993 <br />                                         2007 Texas [30]), humans [31,32]. cases autochthonous vector-borne <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         transmission United States presumed occur undetected, sustaining risk                                         infection blood organ donation mother child [29]. 5,500 <br />                                         individuals infected T. cruzi reported Canada, &gt; 3000 Japan, &gt; 1500                                         Australia [33] &gt; 80,000 Spain [34]. Europe, recognized majority <br />                                         patients remain untreated, index undiagnosed cases 94 &#226;&#8364;&#8220; 96% [26,35].                                         millions infected, dreading onset worsening symptoms,                                         far greatest importance availability options immediate treatment. <br />  <br />                               2. Current clinical etiological treatment Chagas disease <br />                                         Currently, drugs available therapeutic use T. cruzi humans: <br />                                         nifurtimox benznidazole [29]. nitroheterocyclic compounds (Figure <br />                                         1A), discovered 1965 1971, respectively [36]. Nifurtimox 5-nitrofuran <br />                                         derivative; benznidazole 2-nitroimidazole derivative. nitroheterocycles,  <br />  <br />                                        Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01. <br />                             Lepesheva                                                                                               Page 4 <br />  <br />  <br />                                         function prodrugs undergo activation nitro group                                         pathogen mediating cytotoxic effects, likely damage DNA                                         macromolecules [37&#226;&#8364;&#8220;39]. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         Unfortunately, benznidazole nifurtimox variable efficiency different T. <br />                                         cruzi strains [40] considerable adverse effects, especially adults,                                         frequently result treatment discontinuation [9]. Particularly, 50 &#226;&#8364;&#8220; 70% patients treated <br />                                         nifurtimox suffer gastrointestinal disorders, neurologic toxicity occurs                                         50% patients. Benznidazole better tolerated nifurtimox                                           recommended choice treatment [8], produce severe dermatitis <br />                                         bone marrow disorders [41]. <br />  <br />                                         drug approved Food Drug Administration (FDA),                                         potentially obtained special request Center Disease Control used <br />                                         investigational protocols [29]. According recommendations 2005 2007, <br />                                         antitrypanosomal treatment strongly advised cases acute, congenital                                         reactivated infection, children infection, patients 18 years age <br />                                         chronic disease. Drug treatment generally offered adults aged 19 &#226;&#8364;&#8220; 50 <br />                                         years advanced Chagas heart disease, optional &gt; 50 years.                                         debates drugs used late chronic stage, mainly                                         adverse effects difficulties cure assesment. Treatment failures NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         widely reported.   multiple reports indicating treatment <br />                                         benznidazole/nifurtimox prevent reverse development chronic <br />                                         symptoms disease [1,4,7,9,20,42]. extended trials proposed [9]. <br />                                         Attempts improve drug properties altered formulations,                                          undertaken [8].  novo design broad testing safer nitroheterocycles,                                         example, 3-nitrotriazole amines (Figure 1A) currently supported Drugs                                         Neglected Disease initiative (DNDi) appears promising [43]. <br />  <br />                               3. Screening existing antifungal drugs <br />                                         Azole derivatives served successful antifungal drugs                                         decades [44&#226;&#8364;&#8220;46]. act blocking ergosterol biosynthesis fungi inhibition                                         cytochrome P450 enzyme, called sterol 14&#206;&#177;-demethylase (CYP51). CYP51                                         essential sterol biosynthesis happened highly druggable.                                         electronegative nitrogen azole heterocyclic ring forms coordination bond                                         catalytic heme <span id='am-50' about='obo:IMR_0200435' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-51' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-52' property="oboInOwl:hasDbXref" content="KEGG:C00023" datatype="xsd:string"></span><span id='am-53' property="oboInOwl:id" content="IMR:0200435" datatype="xsd:string"></span><span id='am-54' property="rdfs:label" content="Iron" datatype="xsd:string"></span>iron</span>, decreasing reduction potential, noncoordinated, hydrophobic <br />                                         portion azole-containing molecule forms multiple van der Waals contacts                                         <span id='am-43' about='obo:IMR_0001695' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001'><span id='am-44' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-45' property="rdfs:label" content="amino acid" datatype="xsd:string"></span><span id='am-46' property="oboInOwl:hasDbXref" content="CHEBI:33709" datatype="xsd:string"></span><span id='am-47' property="oboInOwl:hasDbXref" content="MeSH:D000596" datatype="xsd:string"></span><span id='am-48' property="oboInOwl:id" content="IMR:0001695" datatype="xsd:string"></span><span id='am-49' property="obo:IAO_0000115" content="Organic compounds that generally contain an amino (-NH2) and a carboxyl (-COOH) group. Twenty alpha-amino acids are the subunits which are polymerized to form proteins." datatype="xsd:string"></span>amino acid</span> residues inside hydrophobic substrate binding cavity enzyme, <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         preventing substrate binding metabolism.  Fe&#226;&#8364;&#8220;N coordination                                         hydrophobic interactions apoprotein moiety ensure tight binding                                         strong, functionally irreversible inhibitory effect catalysis [47]. known <br />                                         small azole derivatives, imidazole phenyl-imidazole, little influence                                         CYP51 activity; effects larger molecules strongly depend                                         composition [48]. noteworthy antifungal azole drugs discovered <br />                                         empirically cellular studies, based antifungal effects produced screening. <br />                                         mechanism action proven sterol analysis (accumulation 14&#206;&#177;- <br />                                         methylated sterol precursors) [49]. Testing potencies CYP51 inhibitors                                         included drug discovery process  highly hydrophobic <br />                                         membrane-bound proteins, fungal CYP51s difficult handle assay vitro. <br />                                         Absence structural information fungal CYP51 complicates drug <br />                                         development. result, currently azoles approved clinical systemic <br />                                         use: ketoconazole, itraconazole, posaconazole, fluconazole voriconazole (Figure 1B). <br />  <br />  <br />                                        Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01. <br />                             Lepesheva                                                                                              Page 5 <br />  <br />  <br />                                         closely related compounds, ravuconazole, TAK-187 UR9825 <br />                                         (Figure 1B) trials/development. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         Similar fungi, T. cruzi completely dependent endogenously produced sterols <br />                                         (ergosterol 24-alkylated derivatives) [50] vital parasite membranes, <br />                                         cell division, growth development processes [47].  idea screening                                         existing antifungal agents potential drugs specific etiological treatment Chagas <br />                                         disease reasonable, especially market                                         safer benznidazole nifurtimox. <br />  <br />                                         report showing topical antifungal drugs, miconazole econazole, inhibit <br />                                         growth T. cruzi (Tulahuen strain) published 1981 [51]. 1984, antiparasitic effect <br />                                         ketoconazole reported vivo mouse models Chagas disease induced                                         different strains parasite [52], including Y strain sensitive                                         nitroderivatives [40]. experiments, 60 mg/kg/bid dosage given 7 days <br />                                         ketoconazole protected mice death, treatment started parasitemia <br />                                         onset. Parasitological cure achieved, presumably short (4 h) life time                                         drug mouse plasma. incidence effects humans treated                                         ketoconazole years known low, authors suggested drug <br />                                         tested therapeutic agent Chagas disease [52].  testing                                         ketoconazole humans demonstrated able eradicate parasitemia NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         treated chronic chagasic patients [53]. years later, itraconazole, triazole <br />                                         derivative ketoconazole display better results. Treatment infected mice <br />                                         120 mg itraconazole/kg/day 7 &#226;&#8364;&#8220; 9 weeks resulted parasitological cure                                         determined negative hemocultures subinoculations, negative serology T. cruzi, <br />                                         absence parasites histological sections following completion therapy [54]. <br />                                         Treatment humans chronic Chagas disease itraconazole produced <br />                                         parasitological cure 53% normalization electrocardiogram (ECG) 48%                                         patients  years follow period) [55].  20 years&#226;&#8364;&#8482; follow  54.3%                                         patients negative parasitological tests used, 60% cases                                         normal ECG traces [56]. Fluconazole did cure mice treatment 200 mg/kg <br />                                         daily dosage 30 days [57], fact agreement relatively weak <br />                                         inhibitory potency T. cruzi CYP51 inhibitor vitro [58,59]. close-derivative <br />                                         voriconazole,  recently reported reveal suppressive effect                                         mouse model (75% survival rate 40 mg/kg/day dosage administered 30 days; <br />                                         Tulahuen strain T. cruzi) [60]. <br />  <br />                                         antifungal drug candidates, TAK-187, UR9825 [61,62], strong <br />                                         potential treatment Chagas disease. potent  D0870, cured short- <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         long-term experimental Chagas disease mice [63], unfortunately failed clinical <br />                                         trials antifungal drug cardiotoxicity (inhibitory effect hERG channel <br />                                         causing QTc prolongation [64]). Finally, 2012, posaconazole  derivative                                         itraconazole) ravuconazole  derivative voriconazole) entered clinical trials                                         Chagas disease Spain, Bolivia Argentina. <br />  <br />                                         Undoubtedly, successful repurposing clinical antifungal drugs Chagas disease                                         cost-efficient way provide immediate treatment needed urgently. <br />                                          second-use application certain limitations.  ravuconazole requires <br />                                         optimization produces suppressive effect animal models Chagas <br />                                         disease, probably largely pharmacokinetics, particularly low bioavailability <br />                                         [65,66]. Posaconazole, extensively studied antichagasic drug candidate                                         J.  Urbina&#226;&#8364;&#8482;s team proved highly potent vivo infection caused <br />                                         multiple, including nitroderivative-resistant strains T. cruzi [66],  <br />  <br />                                        Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01. <br />                             Lepesheva                                                                                               Page 6 <br />  <br />  <br />                                         unfortunately highly expensive complex low-yielding synthetic scheme [67] <br />                                         issues bioavailability. posaconazole cured chronic chagasic <br />                                         patient [68], hospital patient cost 8,000 euro [69], authors reporting NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         success drug indicate  current cost high widespread use                                         endemic countries&#226;&#8364;&#8482; [68]. agents mechanism action lower <br />                                         potential cost needed [69]. <br />  <br />                               4. Experimental inhibitors T. cruzi CYP51 CYP51-structure-based <br />                               drug design development <br />                                         Contrary fungal CYP51s, sterol 14&#206;&#177;-demethyases Trypanosomatidae <br />                                         pathogens, T. cruzi, T. brucei Leishmania infantum (25% average amino acid sequence <br />                                         identity fungal orthologs) characterized biochemically structurally <br />                                         [58,59,70&#226;&#8364;&#8220;72]. Studies inhibition activity reconstituted catalytic reaction                                         vitro revealed susceptibilities protozoan CYP51s antifungal drugs differ <br />                                         significantly fungal orthologs, led identification novel <br />                                         experimental inhibitory scaffolds (Figure 1C) [58,73&#226;&#8364;&#8220;75], including indomethacin amid <br />                                         derivatives (INDO-pyridine scaffold) [75], substrate analog 14&#206;&#177;- <br />                                         methylenecyclopropyl-24,25-dihydrolanosterol (MCP) [74] carboxamide containing &#206;&#178;- <br />                                         phenyl imidazoles (VNI scaffold) [58]. INDO-pyridine derivatives interesting                                         potential dual action vivo: nonazole heme binding CYP51 inhibitors COX2 <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         inhibitors (anti-inflammatory effect). MCP example effective mechanism- <br />                                         based CYP51 inhibitor acts T. cruzi CYP51 selective suicide substrate. Testing                                         effects animal models Chagas disease currently progress, VNI                                         recently proven able cure, 100% cure rate 100% survival,                                         acute chronic forms Chagas disease mice [76]. Nontoxic, orally bioavailable,                                         favorable pharmacokinetics, mutagenicity influence hERG channel, easy                                         synthesize modify, VNI excellent drug candidate, clearly deserving broader <br />                                         attention accelerate progress clinical trials. <br />  <br />                                         CYP51 structural studies explained potencies VNI T. cruzi CYP51 <br />                                         inhibitors [70,77,78] uncovered molecular basis CYP51 exceptional <br />                                         druggability outlined directions undertaken rationally design better <br />                                         drugs. foremost, contrary  particularly human drug-metabolizing CYPs, <br />                                         enormous substrate promiscuity display high structural plasticity, <br />                                         CYP51s structure, especially substrate binding cavity, highly rigid [78].                                         rigidity essential conserved CYP51 catalytic function, order preserve <br />                                         enzyme&#226;&#8364;&#8482;s strict substrate specificity rare P450s step stereospecific <br />                                         reaction. CYP51 reaction, sterol molecule maintained proper <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         catalytic position cytochrome P450 monooxygenation cycles 14&#206;&#177;- <br />                                         methyl group successively converted 14&#206;&#177;-alcohol, 14&#206;&#177;-aldehyde derivative <br />                                         finally C&#226;&#8364;&#8220;C bond cleaved release 14&#206;&#177;-demethylated product                                         <span id='am-61' about='obo:IMR_0200110' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-62' property="oboInOwl:hasDbXref" content="KEGG:C00058" datatype="xsd:string"></span><span id='am-63' property="oboInOwl:id" content="IMR:0200110" datatype="xsd:string"></span><span id='am-64' property="rdfs:label" content="Formic acid" datatype="xsd:string"></span><span id='am-65' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span>formic acid</span> [47]. result rigidity, ligand accommodated inside                                         enzyme binding cavity, best topological fit defining tightest binding  <br />                                         accordingly, strongest inhibitory potency (Figure 2A). Second, substrate access <br />                                         channel CYP51 structures, ligand-free bound different ligands, remains <br />                                         open defined (Figure 2B), bordered helices , F&#226;&#8364;&#179; tip beta 4 <br />                                         hairpin  secondary structural elements enlarged marked Figure 2C). Finally, <br />                                         CYP51 substrate binding cavity extends deeper inside P450 molecule                                         CYPs, reaching helix C N-terminal portion helix (Figure 2C). <br />  <br />                                         Using VNI scaffold example, outline understanding                                         major CYP51 structural features rationally used accelerate drug development <br />  <br />                                        Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01. <br />                             Lepesheva                                                                                              Page 7 <br />  <br />  <br />                                         process. VNI CYP51 binding cavity oriented similar posaconazole (Figure 2A). <br />                                         imidazole ring nitrogen (N3) coordinates heme iron, 2,4-dichlorinated &#206;&#178;-phenyl <br />                                         ring projected deepest portion enzyme substrate binding cavity, 3- <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         ring linear polycycle positioned substrate access channel connected                                         rest inhibitor molecule carboxamide fragment (Figure 2E). carbonyl oxygen <br />                                         fragment forms hydrogen bond catalytic water molecule, connecting <br />                                         inhibitor CYP51 helix disrupting proton delivery route enzyme. <br />                                         amide nitrogen fragment forms hydrogen bond OH group Y103, <br />                                         repositioning chain functionally essential residue, OH group                                         enzymatically active CYP51 enzymes provides support heme H-bonded <br />                                         porphyrin ring D propionate [71]. Based previous experience, location                                         phenyl ring &#206;&#178;-position relative azole ring presence/position                                         Cl atoms ring essential potency scaffold [58], replacement                                         chlorine atom fluorine replacement imidazole ring triazole <br />                                         ring (examples shown [79]) worsens pharmacokinetics (Villalta Lepesheva, <br />                                         unpublished). central core scaffold, including imidazole ring, &#206;&#178;- <br />                                         phenyl ring, carboxamide fragment preserved. <br />  <br />                                         portions molecule potentially derivatized increase                                         potency enhance drug-like properties resulting compounds. Modifications                                         performed regions (Figure 2C F), molecule  long NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         complies Lipinski rules/ADME considerations) separately, aim produce <br />                                         alternative drug candidates; advantageous case acquired <br />                                         resistance. Extension VNI long arm (Figure 2C) mimic surface-binding sub- <br />                                         site, seen access channel entrance T. cruzi CYP51 structure <br />                                         posaconazole [3k1o] [70]. Filling deepest portion CYP51 binding cavity <br />                                         (Figure 2F) appears especially promising  molecules smaller                                         VNI (VNF [70] later NEE [77]) accommodated (Figure 2A) proven                                         highly potent T. cruzi CYP51 inhibitors; ii) portion cavity                                         CYP51-specific, potentially mean substantial decrease influence                                         human CYPs, example, observed addition aromatic ring                                         &#206;&#178;-phenyl ring VNI: modification resulted &gt; 8-fold increase IC50 CYP3A4 <br />                                         inhibition [79]. <br />  <br />                                         Weaker influence human CYPs certainly desirable, importance                                         drugs aimed infectious diseases (especially poor people unlikely                                         permanently use large number additional medications) exaggerated: Drug- <br />                                         metabolizing CYPs essential, inducible activities                                         restored soon administration drug stopped [80]. Temporary inhibition NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         human CYP51 unlikely real problem, humans consume <span id='am-56' about='obo:IMR_0200486' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-57' property="oboInOwl:hasDbXref" content="KEGG:C00187" datatype="xsd:string"></span><span id='am-58' property="rdfs:label" content="Cholesterol" datatype="xsd:string"></span><span id='am-59' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-60' property="oboInOwl:id" content="IMR:0200486" datatype="xsd:string"></span>cholesterol</span> <br />                                         diet, inhibitors human CYP51 considered potential <br />                                         cholesterol-lowering drugs, studies abandoned, mainly high <br />                                         potency statins, drugs block sterol biosynthesis upstream CYP51 reaction <br />                                         [81]. <br />  <br />                                         High heterogeneity T. cruzi population reason development                                         CYP51 inhibitors helpful. 70 different strains parasite <br />                                         (www.dbbm.fiocruz.br/TcruziDB/strain.html, 01/02/2013), joined                                         major groups (TcI &#226;&#8364;&#8220; TcVI), vary broadly sensitivities clinical nitroheterocyclyc <br />                                         drugs benznidazole nifurtimox [40]  apparently, antifungal azoles  <br />                                         including D0870 posaconazole [82,83]. CYP51 gene sequences different T. <br />                                         cruzi strains revealed surprising variability: example, CYP51s Colombiana                                         Sylvio (TcI group) 8 6 amino acid differences CYP51 Tulahuen (TcVI) <br />  <br />  <br />                                        Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01. <br />                             Lepesheva                                                                                                Page 8 <br />  <br />  <br />                                         [84]. Expression genes currently progress hopefully provide                                         explanation altered sensitivities T. cruzi strains azole inhibitors. Given                                         CYP51 regarded housekeeping gene (e.g., CYP51 human differs NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         orthologs macaca dog 3 8 amino acid residues, respectively), finding <br />                                         agrees hypothesis different T. cruzi lineages evolutionarily                                         distant (diverged 88 million years ago [85]), implying sensitivity potential <br />                                         drug targets likely higher variability parasite strains. <br />  <br />                               5. potential drug targets <br />                                         Currently, CYP51 inhibitors advanced drug candidates etiological treatment <br />                                         Chagas disease [9,17,61]. enzymes involved sterol biosynthetic <br />                                         pathway potential serve possible future targets antitrypanosomal <br />                                         chemotherapy. apparent examples HMG-<span id='am-30' about='obo:IMR_0200354' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-31' property="oboInOwl:id" content="IMR:0200354" datatype="xsd:string"></span><span id='am-32' property="rdfs:label" content="CoA" datatype="xsd:string"></span><span id='am-33' property="oboInOwl:hasDbXref" content="KEGG:C00010" datatype="xsd:string"></span><span id='am-34' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span>CoA</span> reductase, humans                                         clinical target statins, <span id='am-6' about='obo:IMR_0200097' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-7' property="oboInOwl:id" content="IMR:0200097" datatype="xsd:string"></span><span id='am-8' property="rdfs:label" content="Farnesyl diphosphate" datatype="xsd:string"></span><span id='am-9' property="oboInOwl:hasDbXref" content="KEGG:C00448" datatype="xsd:string"></span><span id='am-10' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span>farnesyl diphosphate</span> synthase, target bisphosphonates, <br />                                         <span id='am-25' about='obo:IMR_0200481' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-26' property="oboInOwl:hasDbXref" content="KEGG:C00751" datatype="xsd:string"></span><span id='am-27' property="oboInOwl:id" content="IMR:0200481" datatype="xsd:string"></span><span id='am-28' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-29' property="rdfs:label" content="Squalene" datatype="xsd:string"></span>squalene</span> synthase, inhibited quinuclidine derivatives sterol 24- <br />                                         methyltransferase, inhibited azasterols [47]. far,  antiparasitic activity                                         inhibitors vivo reported used combination antifungal <br />                                         azoles, producing synergistic effect [61] suggesting blockage sterol <br />                                         biosynthesis different stages highly advantageous, Chagas disease <br />                                         treatment, sterol-dependent human pathogens, including fungi. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         Synergetic antiparasitic effect antiarrhythmic drug amiodaron posaconazole <br />                                         appears particularly interesting example, amiodaron, recently                                         inhibit <span id='am-1' about='obo:IMR_0200096' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-2' property="oboInOwl:hasDbXref" content="KEGG:C01724" datatype="xsd:string"></span><span id='am-3' property="rdfs:label" content="Lanosterol" datatype="xsd:string"></span><span id='am-4' property="oboInOwl:id" content="IMR:0200096" datatype="xsd:string"></span><span id='am-5' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span>lanosterol</span> synthase, frequently used chronic cardiac Chagas disease <br />                                         patients [86]. opens possibility combining drugs approved                                         clinical use. <br />  <br />                                         number alternative potential targets metabolic pathways crucial                                         T. cruzi survival intracellular development reported, thiol-dependent <br />                                         redox metabolism (trypanothione reductase), glycolysis (glyceraldehyde-3-phosphate <br />                                         dehydrogenase); pentose phosphate pathway, purine salvage pathway <span id='am-35' about='obo:IMR_0001349' typeof='owl:Thing obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001698'><span id='am-36' property="oboInOwl:hasDbXref" content="CHEBI:25608" datatype="xsd:string"></span><span id='am-37' property="rdfs:label" content="nucleoside phosphate" datatype="xsd:string"></span><span id='am-38' property="rdfs:label" content="nucleotide" datatype="xsd:string"></span><span id='am-39' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-40' property="oboInOwl:hasExactSynonym" content="nucleoside phosphate" datatype="xsd:string"></span><span id='am-41' property="obo:IAO_0000115" content="A nucleotide consists of a nitrogen-containing base, a five-carbon sugar, and one or more phosphate groups. Nucleotides can carry chemical energy (e.g. ATP), form coenzymes (e.g. CoA), be used as specific signaling molecules (e.g. cAMP) in the cell. Nucleotides are the subunits of the nucleic acids. " datatype="xsd:string"></span><span id='am-42' property="oboInOwl:id" content="IMR:0001349" datatype="xsd:string"></span>nucleotide</span> <br />                                         synthesis, cysteine proteases (cruzain) kinetoplastid DNA binders (aromatic diamidines) <br />                                         [87]. success difficult predict, particularly lack centralized <br />                                         program perform standardized comparative evaluation. example, <br />                                         kDNA binders receive publicity, highly attractive <br />                                         specific Kinetoplastid pathogens  addition pronounced <br />                                         antiparasitic effects vivo, induce decrease cardiac inflammation [88]. contrast, <br />                                         broadly advertized cruzain inhibitor K777 reported receiving Investigational <br />                                         New Drug status [69], apparently despite hepatotoxicity [61] suppressive <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         antiparasitic effect mice dogs.  long uneasy path involving validation                                         druggability, lead optimization lies ahead alternative drug targets. Right                                         CYP51 inhibitors closer offering cure Chagas disease. <br />  <br />                               6. Conclusion <br />                                         screening design drugs treatment Chagas disease promising. <br />                                          mutually beneficial. lack effort coordination <br />                                         severely halts progress. Including promising drug candidates VNI                                         derivatives sphere pharmaceutical company, foundation                                         partnership claim devoted success drug discovery neglected tropical <br />                                         diseases developed integrated strategy evaluating medicinal chemistry, <br />                                         safety, pharmacokinetics, pharmacodynamics,  [89]. highly helpful                                         advancing leading compounds clinical trials. <br />  <br />  <br />                                        Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01. <br />                             Lepesheva                                                                                               Page 9 <br />  <br />  <br />                                         years follow results posaconazole/ravuconazole clinical trials <br />                                         available. meantime, additional phenotypic high throughput <br />                                         screenings (HTS) completed, bringing new hits new hopes. noteworthy NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         statements  appear reports HTS-conducting teams)                                         excluding libraries hits &#226;&#8364;&#732;look like CYP51 inhibitors&#226;&#8364;&#8482; sound <br />                                         especially reasonable. contrary, hits thoroughly studied                                         higher probability success vs. attrition. fact, optimization HTS hit (plant <br />                                         antifungal agent fenarimol) DNDi [90] led development highly <br />                                         promising potent nonazole drug candidates, costructures T. cruzi CYP51 <br />                                         (PDB <span id='am-55' about='oboInOwl:id' typeof='owl:Thing'>ID</span> 3zg2 3zg3) [91] facilitate finishing steps drug discovery <br />                                         process. Impartial comprehensive comparative preclinical testing advanced <br />                                         experimental CYP51 inhibitors appears good way offer safer affordable <br />                                         specific treatment Chagas disease outcomes clinical trials posaconazole <br />                                         ravuconazole clearer. <br />  <br />                               7. Expert opinion <br />                                         major advance field certainly growing appreciation Chagas disease                                         persistent parasitic infection treated infectious disease requires <br />                                         parasitological cure, regardless stage, order prevent development clinical <br />                                         symptoms.  highly encouraging information efficacy current, NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         optimal largely underutilized, antiparasitic drugs achieving cure, reducing                                         disease severity reversing chronic clinical symptoms killing parasite.                                         major weaknesses appear result long-term neglect gross underfunding.                                         include lack easily available reliable diagnostic procedures, shortages drug <br />                                         availability  important, absence unanimous opinion criteria cure <br />                                         (e.g., serological tests used main assessment cure, long-lasting immune <br />                                         memory requires lengthy follow periods order indicate treatment worked). <br />                                         Development standardized sensitive quantitative PCR analyses protocols conduct <br />                                         preclinical animal studies allow reliable comparison new drug efficacies <br />                                         promising. <br />  <br />                                         fact doctors recommended prescribe specific treatment Chagas <br />                                         disease encouraging, infected patients, search new, <br />                                         better safer drugs. Positive results eventually overcome low impetus                                         based lack belief drugs widely used proven efficacious. <br />                                         detailed  availability T. cruzi CYP51 structure makes structure-based <br />                                         rational lead optimization quite straightforward, multidisciplinary approach <br />                                         involving chemistry, biochemistry, structural cellular biology, pharmacology NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         toxicology, comprehensive testing best drug candidates preformed                                         centralized unbiased organization required.  better knowledge biology                                         genetics various T. cruzi strains, eventually distinguished                                         different species, needed.  infections caused drug-resistant <br />                                         strains parasite, Colombiana, combination therapy include CYP51 <br />                                         inhibitors potent multiplying intracellular amastigotes                                         trypomastigotes [58,76] nitroderivatives seriously considered.                                         allow decrease dosage  example, benznidazole alleviation                                         effects. <br />  <br />                                         organizations, including DNDi, formed invest                                         screenings programs drug discovery implementations [89], doubt <br />                                         future directions involve high throughput searches new active compounds                                         alternative mechanisms action mining T. cruzi genome novel potential <br />  <br />  <br />                                        Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01. <br />                             Lepesheva                                                                                                    Page 10 <br />  <br />  <br />                                         alternative drug targets. efforts eventually lead important discoveries, <br />                                         advancing basic knowledge antimicrobial chemotherapy. New sets potent drugs <br />                                         supported efficient vector control programs hopefully work NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         devastating disease eliminated. <br />  <br />                               Bibliography <br />                                         Papers special note highlighted (&#226;&#8364;&#162;) considerable <br />                                         (&#226;&#8364;&#162;&#226;&#8364;&#162;) readers. <br />  <br />                                         1&#226;&#8364;&#162;. Rassi Jr, Rassi  Marin-Neto JA. Chagas disease. Lancet. 2012; 375:1388&#226;&#8364;&#8220;402. paper <br />                                               provides interesting update current status Chagas disease. [PubMed: 20399979] <br />                                         2. Higuchi, MdL; Benvenuti, LA.; Martins Reis, M., et al. Pathophysiology heart Chagas&#226;&#8364;&#8482; <br />                                            disease: current status new developments. Cardiovasc Res. 2003; 60:96&#226;&#8364;&#8220;107. [PubMed: <br />                                            14522411] <br />                                         3. Tanowitz HB, Kirchhoff LV, Simon D, et al. Chagas&#226;&#8364;&#8482; disease. Clin Microbiol Rev. 1992; 5:400&#226;&#8364;&#8220;19. <br />                                            [PubMed: 1423218] <br />                                         4. Pinto Dias JC. treatment Chagas disease (South American trypanosomiasis). Ann Intern <br />                                            Med. 2006; 144:772&#226;&#8364;&#8220;4. [PubMed: 16702594] <br />                                         5. Pereira KS, Schmidt FL, Guaraldo  et al. Chagas&#226;&#8364;&#8482; disease foodborne illness. J Food Prot. <br />                                            2009; 72:441&#226;&#8364;&#8220;6. [PubMed: 19350996] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         6. Coura JR, Borges-Pereira J. Chagas disease: known improved:                                            systemic review. Rev Soc Bras Med Trop. 2012; 45:286&#226;&#8364;&#8220;96. [PubMed: 22760123] <br />                                         7. Sosa-Estani S, Segura EL. Etiological treatment patients infected Trypanosoma cruzi: <br />                                            experiences Argentina. Curr Opin Infect Dis. 2006; 6:583&#226;&#8364;&#8220;7. [PubMed: 17075335] <br />                                         8. Salomon CJ. century chagas&#226;&#8364;&#8482; disease: overview novel approaches nifurtimox                                            benznidazole delivery systems. J Pharm Sci. 2012; 101:888&#226;&#8364;&#8220;94. [PubMed: 22161779] <br />                                         9&#226;&#8364;&#162;. Bern C. Antitrypanosomal therapy chronic Chagas&#226;&#8364;&#8482; disease. N Engl J Med. 2011; 364:2527&#226;&#8364;&#8220;34. <br />                                               paper summarized information current diagnostics clinical etiological <br />                                               treatment Chagas disease. [PubMed: 21714649] <br />                                         10. Prata  Chagas&#226;&#8364;&#8482; disease. Infect Dis Clin North  1994; 8:61&#226;&#8364;&#8220;76. [PubMed: 8021449] <br />                                         11. Altclas J, Sinagra  Dictar M, et al. Chagas disease bone marrow transplantation: approach <br />                                             preemptive therapy. Bone Marrow Transplant. 2005; 36:123&#226;&#8364;&#8220;9. [PubMed: 15908978] <br />                                         12. Sartori AMC, Ibrahim KY, Nunes, et al. Manifestations Chagas disease (American <br />                                             trypanosomiasis) patients HIV/AIDS. Ann Trop Med Parasitol. 2007; 101:31&#226;&#8364;&#8220;50. <br />                                             [PubMed: 17244408] <br />                                         13. Aufderheide AC, Salo W, Madden M, et al. 9,000-year record Chagas&#226;&#8364;&#8482; disease. Proc Natl <br />                                             Acad Sci USA. 2004; 101:2034&#226;&#8364;&#8220;9. [PubMed: 14766963] <br />                                         14&#226;&#8364;&#162;. Bustamante JM, Tarleton RL. Methodological advances drug discovery Chagas disease. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                               Expert Opin Drug Discov. 2011; 6:653&#226;&#8364;&#8220;61. review outlines new approaches fast vivo <br />                                               screening new antitrypanosomal drug candidates. [PubMed: 21712965] <br />                                         15. Bastien, J. kiss keath: Chagas&#226;&#8364;&#8482; disease Americas. Univ. Utah Press; Salt Lake City: <br />                                             1998. <br />                                         16. Technical Report Series 905 Press Release. World Health Organization; Geneva: 2002. <br />                                             Second report expert committee control Chagas disease; p. 85Available <br />                                              http://apps int/bookorders/anglais/detart1.jsp?codlan=1<span id='am-18' about='obo:IMR_0200083' typeof='owl:Thing obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0001349 obo:IMR_0000001 obo:IMR_0001698'><span id='am-19' property="oboInOwl:hasDbXref" content="KEGG:C00020" datatype="xsd:string"></span><span id='am-20' property="oboInOwl:id" content="IMR:0200083" datatype="xsd:string"></span><span id='am-21' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-22' property="rdfs:label" content="AMP" datatype="xsd:string"></span><span id='am-23' property="rdfs:label" content="Adenosine 5&apos;-monophosphate" datatype="xsd:string"></span><span id='am-24' property="oboInOwl:hasExactSynonym" content="Adenosine 5&apos;-monophosphate" datatype="xsd:string"></span>amp</span>;codcol=10&amp;codcch=905# <br />                                         17. World Health Organization  . Chagas disease: Control Elimination. UNDP/World Bank/ <br />                                              2010. post annual reports  http://www int/topics/chagas_disease  <br />                                         18. Urbina JA. Parasitological cure Chagas disease: possible? relevant? Mem Inst Oswaldo <br />                                             Cruz. 1999; 94:349&#226;&#8364;&#8220;55. [PubMed: 10677754] <br />                                         19&#226;&#8364;&#162;. Tarleton RL, Zhang L, Downs MO. &#226;&#8364;&#339;Autoimmune rejection&#226;&#8364;? neonatal heart transplants                                               experimental Chagas disease parasite-specific response infected host tissue. Proc Natl <br />                                               Acad Sci USA. 1997; 94:3932&#226;&#8364;&#8220;7. work proven chronic form Chagas                                               treated infectious disease. [PubMed: 9108082] <br />  <br />  <br />                                        Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01. <br />                             Lepesheva                                                                                                   Page 11 <br />  <br />  <br />                                         20. Viotti R, Vigliano C, Armenti H, et al. Treatment chronic Chagas&#226;&#8364;&#8482; disease benznidazole: <br />                                             clinical serologic evolution patients long-term follow  Heart J. 1994; 127:151&#226;&#8364;&#8220; <br />                                             62. [PubMed: 8273735] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         21. Andrade SG, Stocker-Guerret S, Pimentel  et al. Reversibility cardiac fibrosis mice <br />                                             chronically infected Trypanosoma cruzi, specific chemotherapy. Mem Inst Oswaldo <br />                                             Cruz. 1991; 86:187&#226;&#8364;&#8220;200. [PubMed: 1842413] <br />                                         22. Kaplan D, Ferrari  Bergami PL, et al. Antibodies ribosomal P proteins Trypanosoma cruzi                                             Chagas disease possess functional autoreactivity heart tissue differ anti-P <br />                                             autoantibodies lupus. Proc Natl Acad Sci USA. 1997; 94:10301&#226;&#8364;&#8220;6. [PubMed: 9294205] <br />                                         23. Docampo R, Schmu&#195;&#177;is GA. Sterol biosynthesis inhibitors: potential chemotherapeutics                                             chagas disease. Parasitol Today. 1997; 13:129&#226;&#8364;&#8220;30. [PubMed: 15275097] <br />                                         24. Leslie M. Drug developers finally aim neglected disease. Science. 2011; 333:933&#226;&#8364;&#8220;5. <br />                                             [PubMed: 21852468] <br />                                         25. Tarleton RL, Reithinger R, Urbina JA, et al. challenges Chagas disease - grim outlook                                             glimmer hope? PLoS Med. 2007; 4:e332. [PubMed: 18162039] <br />                                         26. Klein N, Hurwitz  Durvasula R. Globalization Chagas disease: growing concern                                             nonendemic countries. Epidemiol Res Int. 2012:1&#226;&#8364;&#8220;13. Article ID 136793. <br />                                         27&#226;&#8364;&#162;. Hotez PJ. Neglected infections poverty United States America. PLoS Negl Trop Dis. <br />                                               2008; 2:e256. Globalization Ghagas disease problem (USA). [PubMed: 18575621] <br />                                         28&#226;&#8364;&#162;. Hanford EJ, Zhan FB, Lu Y, et al. Chagas disease Texas: recognizing significance                                               implications evidence literature. Soc Sci Med. 2007; 65:60&#226;&#8364;&#8220;79. Globalization Ghagas <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                               disease problem (USA). [PubMed: 17434248] <br />                                         29. Bern C, Kjos S, Yabsley MJ, et al. Trypanosoma cruzi Chagas&#226;&#8364;&#8482; disease United States. <br />                                             Clin Microbiol Rev. 2011; 24:655&#226;&#8364;&#8220;81. [PubMed: 21976603] <br />                                         30. Esch KJ, Petersen CA. Transmission epidemiology zoonotic protozoal diseases                                             companion animals. Clin Microbiol Rev. 2013; 26:58&#226;&#8364;&#8220;85. [PubMed: 23297259] <br />                                         31. Barry MA, Weatherhead JE, Hotez PJ, et al. Childhood parasitic infections endemic United <br />                                             States. Pediatr Clin North  2013; 60:471&#226;&#8364;&#8220;85. [PubMed: 23481112] <br />                                         32&#226;&#8364;&#162;. Barry MA, Bezek S, Serpa JA, et al. Neglected infections poverty Texas rest                                               United States: management treatment options. Clin Pharmacol Ther. 2012; 92:170&#226;&#8364;&#8220;81. <br />                                               Globalization Ghagas disease problem (USA). [PubMed: 22760004] <br />                                         33. Coura JR, Vi&#195;&#177;as PA. Chagas disease: new worldwide challenge. Nature. 2010; 465:S6&#226;&#8364;&#8220;7. <br />                                             [PubMed: 20571554] <br />                                         34. Schmunis GA, Yadon ZE. Chagas disease: Latin American health problem world <br />                                             health problem. Acta Trop. 2010; 115:14&#226;&#8364;&#8220;21. [PubMed: 19932071] <br />                                         35&#226;&#8364;&#162;. Basile L, Jansa JM, Carlier Y, et al. Chagas disease European countries: challenge                                               surveillance  Euro Surveill. 2011; 16:1&#226;&#8364;&#8220;10. Globalization Ghagas disease problem <br />                                               (Europe). <br />                                         36. Mady C, Ianni BM, Souza JLJ. Benznidazole Chagas disease: old drug answer <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             old problem? Expert Opin Investig Drugs. 2008; 17:1427&#226;&#8364;&#8220;33. <br />                                         37. Raether W, Hanel H. Nitroheterocyclic drugs broad spectrum activity. Parasitol Res. 2003; <br />                                             S1:S19&#226;&#8364;&#8220;39. [PubMed: 12811546] <br />                                         38. Mejia  Hall BS, Taylor MC, et al. Benznidazole-resistance Trypanosoma cruzi readily <br />                                             acquired trait arise independently single population. J Infect Dis. 2012; 206:220&#226;&#8364;&#8220;8. <br />                                             [PubMed: 22551809] <br />                                         39. Wilkinson SR, Taylor MC, Horn D, et al. mechanism cross-resistance nifurtimox                                             benznidazole trypanosomes. Proc Natl Acad Sci USA. 2008; 105:5022&#226;&#8364;&#8220;7. [PubMed: 18367671] <br />                                         40&#226;&#8364;&#162;. Filardi LS, Brener  Susceptibility natural resistance Trypanosoma cruzi strains drugs <br />                                               used clinically Chagas disease. Trans R Soc Trop Med Hyg. 1987; 81:755&#226;&#8364;&#8220;9. report <br />                                               showing drug susseptibility varyes significally different T. cruzi strains. [PubMed: <br />                                               3130683] <br />                                         41. Castro JA, Mecca MM, Bartel LC. Toxic effects drugs used treat Chagas&#226;&#8364;&#8482; disease <br />                                             (American trypanosomiasis). Hum Exp Toxicol. 2006; 8:471&#226;&#8364;&#8220;9. [PubMed: 16937919] <br />  <br />  <br />  <br />                                        Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01. <br />                             Lepesheva                                                                                                   Page 12 <br />  <br />  <br />                                         42. Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes treating chronic Chagas <br />                                             disease benznidazole versus treatment. nonrandomized trial. Ann Intern Med. 2006; <br />                                             144:724&#226;&#8364;&#8220;34. [PubMed: 16702588] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         43. Papadopoulou MV, Trunz BB, Bloomer WD, et al. Novel 3-nitro-1H-1,2,4-triazole-based aliphatic <br />                                             aromatic amines anti-Chagasic agents. J Med Chem. 2011; 54:8214&#226;&#8364;&#8220;23. [PubMed: <br />                                             22023653] <br />                                         44. Bennett JE. Chemotherapy systemic mycoses. N Engl J Med. 1974; 290:320&#226;&#8364;&#8220;3. [PubMed: <br />                                             4588286] <br />                                         45. Maertens JA. History development azole derivatives. Clin Microbiol Infect. 2004; <br />                                             10:101&#226;&#8364;&#8220;10. <br />                                         46. Ostrosky-Zeichner L, Casadevall  Galgiani JN, et al. insight antifungal pipeline: <br />                                             selected new molecules  Nat Rev Drug Discov. 2010; 9:719&#226;&#8364;&#8220;27. [PubMed: 20725094] <br />                                         47. Lepesheva GI, Villalta F, Waterman MR. Targeting Trypanosoma cruzi sterol 14&#206;&#177;-demethylase <br />                                             (CYP51). Adv Parasitol. 2011; 75:65&#226;&#8364;&#8220;87. [PubMed: 21820552] <br />                                         48. Correia, MA.; Ortiz Montellano, PR. Inhibition cytochrome P450 enzymes.  Ortiz                                             Montellano, PR., editor. Cytochrome P450: structure, mechanism, biochemistry. Plenum <br />                                             Publishing Corp; New York: 2005. p. 246-322. <br />                                         49. Vanden Bossche, H., editor. Mode action pyridine, pyrimidine azole antifungals. Ellis <br />                                             Horwood; Chichester: 1988. p. 79-119. <br />                                         50. Roberts CW, McLeod R, Rice DW, et al. Fatty acid sterol metabolism: potential antimicrobial <br />                                             targets apicomplexan trypanosomatid parasitic protozoa. Mol Biochem Parasitol. 2003; <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             126:129&#226;&#8364;&#8220;42. [PubMed: 12615312] <br />                                         51&#226;&#8364;&#162;. Docampo R, Moreno SN, Turrens JF, et al. Biochemical ultrastructural alterations produced <br />                                               miconazole econazole Trypanosoma cruzi. Mol Biochem Parasitol. 1981; 3:169&#226;&#8364;&#8220;80. <br />                                               report antitrypanosomal activity antifungal azole. [PubMed: 6265775] <br />                                         52. McCabe  Remington JS, Araujo FG. Ketoconazole inhibition intracellular multiplication                                             Trypanosoma cruzi protection mice lethal infection organism. J Infect Dis. <br />                                             1984; 150:594&#226;&#8364;&#8220;601. [PubMed: 6092485] <br />                                         53. Brener  Can&#195;&#167;ado JR, Galvao LM, et al. experimental clinical assay ketoconazole                                             treatment Chagas disease. Mem Inst Oswaldo Cruz. 1993; 88:149&#226;&#8364;&#8220;53. [PubMed: 8246750] <br />                                         54. McCabe  Remington JS, Araujo FG. vitro vivo effects itraconazole                                             Trypanosoma cruzi. J Trop Med Hyg. 1986; 35:280&#226;&#8364;&#8220;4. [PubMed: 3006529] <br />                                         55. Apt W, Aguilera X, Arribada  et al. Treatment chronic Chagas&#226;&#8364;&#8482; disease itraconazole                                             allopurinol. J Trop Med Hyg. 1998; 59:133&#226;&#8364;&#8220;8. [PubMed: 9684641] <br />                                         56. Apt W, Arribada  Zulantay  et al. Treatment Chagas&#226;&#8364;&#8482; disease itraconazole: <br />                                             electrocardiographic parasitological conditions 20 years follow  J Antimicrob <br />                                             Chemother. 2013; 68(9):2164&#226;&#8364;&#8220;9. [PubMed: 23645584] <br />                                         57. Campos R, Amato Neto V, Moreira AA, et al. Evaluation therapeutic activity fluconazole <br />                                             acute experimental infection caused Trypanosoma cruzi. Rev Hosp Clin Fac Med Sao Paulo. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             1992; 47:174&#226;&#8364;&#8220;5. [PubMed: 1340597] <br />                                         58. Lepesheva GI, Ott RD, Hargrove TY, et al. Sterol 14 alpha-demethylase potential target                                             antitrypanosomal therapy: enzyme inhibition parasite cell growth. Chem Biol. 2007; 14:1283&#226;&#8364;&#8220; <br />                                             93. [PubMed: 18022567] <br />                                         59. Lepesheva GI, Zaitseva NG, Nes WD, et al. CYP51 Trypanosoma cruzi: phyla-specific <br />                                             residue B&#226;&#8364;&#8482; helix defines substrate preferences sterol 14alpha-demethylase. J Biol Chem. <br />                                             2006; 281:3577&#226;&#8364;&#8220;85. [PubMed: 16321980] <br />                                         60. Gulin JEN, Eagleson MA, Postan M, et al. Efficacy voriconazole murine model acute <br />                                             Trypanosoma cruzi infection. J Antimicrob Chemother. 2013; 68:888&#226;&#8364;&#8220;94. [PubMed: 23212113] <br />                                         61. Urbina JA. New insights Chagas&#226;&#8364;&#8482; disease treatment. Drug Fut. 2010; 35:409&#226;&#8364;&#8220;19. <br />                                         62. Urbina JA. Specific chemotherapy Chagas disease: relevance, current limitations new <br />                                             approaches. Acta Trop. 2010; 115:55&#226;&#8364;&#8220;68. [PubMed: 19900395] <br />                                         63. Urbina JA, Payares G, Molina J, et al. Cure short- long-term experimental Chagas&#226;&#8364;&#8482; disease <br />                                             using D0870. Science. 1996; 273:969&#226;&#8364;&#8220;71. [PubMed: 8688084] <br />  <br />  <br />  <br />                                        Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01. <br />                             Lepesheva                                                                                                   Page 13 <br />  <br />  <br />                                         64. Williams KJ, Denning DW. Termination development D0870. J Antimicrob Chemother. <br />                                             2001; 47:720&#226;&#8364;&#8220;1. [PubMed: 11328795] <br />                                         65. Diniz Lde F, Caldas  Guedes PM, et al. Effects ravuconazole treatment parasite load NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             immune response dogs experimentally infected Trypanosoma cruzi. Antimicrob Agents <br />                                             Chemother. 2010; 54:2979&#226;&#8364;&#8220;86. [PubMed: 20404124] <br />                                         66. Urbina JA. Ergosterol biosynthesis drug development Chagas disease. Mem Inst Oswaldo <br />                                             Cruz. 2009; 104(Suppl 1):311&#226;&#8364;&#8220;18. [PubMed: 19753490] <br />                                         67. Dobish MC, Villalta F, Waterman MR, et al. Organocatalytic, enantioselective synthesis VNI:                                             robust therapeutic development platform Chagas, neglected tropical disease. Org Lett. 2012; <br />                                             14:6322&#226;&#8364;&#8220;5. [PubMed: 23214987] <br />                                         68&#226;&#8364;&#162;. Pinazo MJ, Espinosa G, Gallego M, et al. Successful treatment posaconazole patient <br />                                               chronic Chagas disease systemic lupus erythematosus. J Trop Med Hyg. 2010; <br />                                               82:583&#226;&#8364;&#8220;7. Cure chronic chagasic patient posaconazole. [PubMed: 20348503] <br />                                         69. Clayton J. Chagas disease: pushing pipeline. Nature. 2010; 465:S12&#226;&#8364;&#8220;15. [PubMed: <br />                                             20571548] <br />                                         70. Lepesheva GI, Hargrove TY, Anderson S, et al. Structural insights inhibition sterol 14 <br />                                             alpha-demethylase human pathogen Trypanosoma cruzi. J Biol Chem. 2010; 285:25582&#226;&#8364;&#8220;90. <br />                                             [PubMed: 20530488] <br />                                         71. Lepesheva GI, Park HW, Hargrove TY, et al. Crystal structures Trypanosoma brucei sterol 14 <br />                                             alpha-demethylase implications selective treatment human infections. J Biol Chem. <br />                                             2010; 285:1773&#226;&#8364;&#8220;80. [PubMed: 19923211] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         72. Hargrove TY, Wawrzak  Liu J, et al. Substrate preferences catalytic parameters determined <br />                                             structural characteristics sterol 14&#206;&#177;-demethylase (CYP51) Leishmania infantum. J Biol <br />                                             Chem. 2011; 286:26838&#226;&#8364;&#8220;48. [PubMed: 21632531] <br />                                         73. Lepesheva G, Hargrove T, Kleshchenko Y, et al. CYP51: major drug target cytochrome <br />                                             P450 superfamily. Lipids. 2008; 43:1117&#226;&#8364;&#8220;25. [PubMed: 18769951] <br />                                         74. Hargrove TY, Wawrzak  Liu J, et al. Structural complex sterol 14&#206;&#177;-demethylase (CYP51) <br />                                             14&#206;&#177;-methylenecyclopropyl-&#206;&#8221;7-24, 25-dihydrolanosterol. J <span id='am-12' about='obo:IMR_0001362' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001'><span id='am-13' property="oboInOwl:hasDbXref" content="CHEBI:25054" datatype="xsd:string"></span><span id='am-14' property="obo:IAO_0000115" content="Organic molecule that is insoluble in water but tends to dissolve in nonpolar organic solvent." datatype="xsd:string"></span><span id='am-15' property="rdfs:label" content="lipid" datatype="xsd:string"></span><span id='am-16' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-17' property="oboInOwl:id" content="IMR:0001362" datatype="xsd:string"></span>Lipid</span> Res. 2012; 53:311&#226;&#8364;&#8220;20. <br />                                             [PubMed: 22135275] <br />                                         75. Konkle  Hargrove TY, Kleshchenko YY, et al. Indomethacin amides novel molecular <br />                                             scaffold targeting Trypanosoma cruzi sterol 14 alpha-demethylase. J Med Chem. 2009; <br />                                             52:2846&#226;&#8364;&#8220;53. [PubMed: 19354253] <br />                                         76&#226;&#8364;&#162;. Villalta F, Dobish MC, Nde PN, et al. VNI cures acute chronic experimental Chagas disease. <br />                                               J Infect Dis. 2013; 208:504&#226;&#8364;&#8220;11. Curative effect new experimental T.cruzi-specific CYP51 <br />                                               inhibitor VNI mice. [PubMed: 23372180] <br />                                         77. Andriani G, Amata E, Beatty J, et al. Antitrypanosomal lead discovery: identification ligand- <br />                                             efficient inhibitor Trypanosoma cruzi CYP51 parasite growth. J Med Chem. 2013; <br />                                             56:2556&#226;&#8364;&#8220;67. [PubMed: 23448316] <br />                                         78. Lepesheva GI, Waterman MR. Sterol 14alpha-demethylase (CYP51) therapeutic target                                             human trypanosomiasis leishmaniasis. Curr Med Chem. 2011; 11:2060&#226;&#8364;&#8220;71. [PubMed: <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             21619513] <br />                                         79&#226;&#8364;&#162;. Hargrove TY, Kim K, Nazar&#195;&#169; Correia Soeiro M, et al. CYP51 structures structure-based <br />                                               development novel, pathogen-specific inhibitory scaffolds. Int J Parasitol Drugs Drug Resist. <br />                                               2012; 2:178&#226;&#8364;&#8220;86. Initial steps CYP51 structure-based VNI scaffold development. [PubMed: <br />                                               23504044] <br />                                         80. Guengerich FP. Cytochrome P450s enzymes drug metabolism toxicity. AAPS J. <br />                                             2006; 8:E101&#226;&#8364;&#8220;11. [PubMed: 16584116] <br />                                         81. Lepesheva GI, Waterman MR. Sterol 14alpha-demethylase cytochrome P450 (CYP51), P450                                             biological kingdoms. Biochim Biophys Acta. 2007; 1770:467&#226;&#8364;&#8220;77. [PubMed: 16963187] <br />                                         82. Molina J, Brener  Romanha AJ, et al. vivo activity bis-triazole D0870 drug- <br />                                             susceptible drug-resistant strains protozoan parasite Trypanosoma cruzi. J Antimicrob <br />                                             Chemother. 2000; 46:137&#226;&#8364;&#8220;40. [PubMed: 10882704] <br />                                         83. Molina J, Martins-Filho O, Brener  et al. Activities triazole derivative SCH 56592 <br />                                             (posaconazole) drug-resistant strains protozoan parasite Trypanosoma <br />  <br />  <br />                                        Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01. <br />                             Lepesheva                                                                                                 Page 14 <br />  <br />  <br />                                             (Schizotrypanum) cruzi immunocompetent immunosuppressed murine hosts. Antimicrob <br />                                             Agents Chemother. 2000; 44:150&#226;&#8364;&#8220;5. [PubMed: 10602737] <br />                                         84. Soeiro, MdNC.; Souza, EM.; da Silva, CF., et al. Antiparasitic activity sterol 14&#206;&#177;- <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             demethylase (CYP51) inhibitor VNI drug-resistant strains Trypanosoma cruzi: vitro <br />                                             vivo studies. Antimicrob Agents Chemother. 2013; 57(9):4151&#226;&#8364;&#8220;63. [PubMed: 23774435] <br />                                         85. Kawashita SY, Sanson GFO, Fernandes O, et al. Maximum-likelihood divergence <span id='am-11' about='oboInOwl:date' typeof='owl:Thing'>date</span> estimates <br />                                             based rRNA gene sequences suggest scenarios Trypanosoma cruzi intraspecific <br />                                             evolution. Mol Biol Evol. 2001; 18:2250&#226;&#8364;&#8220;9. [PubMed: 11719574] <br />                                         86. Benaim G, Sanders JM, Garcia-March&#195;&#161;n Y, et al. Amiodarone intrinsic anti-Trypanosoma <br />                                             cruzi activity acts synergistically posaconazole. J Med Chem. 2006; 49:892&#226;&#8364;&#8220;9. [PubMed: <br />                                             16451055] <br />                                         87&#226;&#8364;&#162;. Soeiro MN, Castro SL. Trypanosoma cruzi targets new chemotherapeutic approaches. <br />                                               Expert Opin Ther Targets. 2009; 13:105&#226;&#8364;&#8220;21. paper provides deetailed review potential <br />                                               alternative drug targets T. cruzi. [PubMed: 19063710] <br />                                         88. Soeiro MNC, Werbovetz K, Boykin DW, et al. Novel amidines analogues promising agents <br />                                             intracellular parasites: systematic review. Parasitology. 2013; 140:929&#226;&#8364;&#8220;51. [PubMed: <br />                                             23561006] <br />                                         89. Chatelain E, Ioset JR. Drug discovery development neglected diseases: DNDi model. <br />                                             Drug Des Devel Ther. 2011; 5:175&#226;&#8364;&#8220;81. <br />                                         90. Keenan M, Abbott MJ, Alexander PW, et al. Analogues fenarimol potent inhibitors                                             Trypanosoma cruzi efficacious murine model Chagas disease. J Med Chem. 2012; <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             55:4189&#226;&#8364;&#8220;204. [PubMed: 22536986] <br />                                         91. Hargrove TY, Wawrzak  Alexander P, et al. T. cruzi CYP51 complexes pyridine-based <br />                                             drug candidates Chagas disease: structural basis pathogen-selectivity. J Biol Chem. 2013 <br />                                             Epub ahead print. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                        Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01. <br />                             Lepesheva                                                                                              Page 15 <br />  <br />  <br />                                                                                 Article highlights <br />                                               &#226;&#8364;&#162;    Broader use antiparasitic therapy treat intermediate chronic forms NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                    Chagas disease brings positive results, supporting concept                                                    treated infection cured. <br />                                               &#226;&#8364;&#162;    Current clinical drugs, benznidazole nifurtimox,  toxic <br />                                                    better agents needed. <br />                                               &#226;&#8364;&#162;    date, inhibitors sterol 14&#206;&#177;-demethylase (CYP51) advanced <br />                                                    new drug candidates: antifungal azoles, posaconazole ravuconazole                                                    evaluated clinical trials. <br />                                               &#226;&#8364;&#162;    Repurposing clinical antifungal drugs market                                                    indication cost-efficient way add arsenal available <br />                                                    antichagasic chemotherapy;  selected inhibitors fungal <br />                                                    CYP51, certain limitations. <br />                                               &#226;&#8364;&#162;    Availability X-ray structure T. cruzi CYP51, complexes novel <br />                                                    experimental protozoa-specific CYP51 inhibitors active vivo makes <br />                                                    lead optimization process straightforward. <br />                                               &#226;&#8364;&#162;    Including novel drug candidates, VNI derivatives, sphere <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                    drug developing companies highly helpful advancing <br />                                                    passage clinical trials. <br />                                         box summarizes key points contained article. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                        Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01. <br />                             Lepesheva                                                                                       Page 16 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         Figure 1. Compounds active T. cruzi <br />                                          Nitroheterocycles: antichagasic drugs benznidazole nifurtimox experimental <br />                                         compound 42 ref [43]. B. Antifungal drugs drug candidates. C. Examples                                         experimental inhibitors T. cruzi CYP51. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                        Expert Opin Drug Discov. Author manuscript; available PMC 2014 December 01. <br />                             Lepesheva                                                                                           Page 17 <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         Figure 2. T. cruzi CYP51 structure template rational drug design <br />                                         orientation protein panels similar (~ distal view P450 molecule).  <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                         CYP51-structure-based inhibitory pharmacophore including imidazoles VNI (cyan, PDB ID <br />                                         [3gw9]), VNF (brick, [3skw]), NEE (purple, [4h6o]); triazoles posaconazole (blue, <br />                                         [3k1o]), fluconazole (pink, [3lfd]); pyridine derivative UDO (goldenrod, [3zg2])                                         substrate analog MCP (olive, [3p99]). B. Overall semitransparent surface representation                                         CYP51 molecule, enlarged view secondary structural elements forming                                         substrate access channel binding cavity seen c. C. secondary <br />                                         structural elements forming entrance substrate binding channel colored                          <br /> </body></html>